Cargando…
High-dose-rate brachytherapy – a novel treatment approach for primary clear cell adenocarcinoma of male urethra
The incidence of male urethral cancer is rare with age preponderance of 50 to 60 years. The standard management approach is surgery. Here, we present a novel treatment approach for male urethral cancer. Thirty-six year old male, case of primary clear cell adenocarcinoma of urethra who refused surger...
Autores principales: | Lewis, Shirley, Pal, Mahendra, Bakshi, Ganesh, Ghadi, Yogesh G., Menon, Santosh, Murthy, Vedang, Mahantshetty, Umesh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4499518/ https://www.ncbi.nlm.nih.gov/pubmed/26207115 http://dx.doi.org/10.5114/jcb.2015.52316 |
Ejemplares similares
-
Testicular shielding in penile brachytherapy
por: Bindal, Arpita, et al.
Publicado: (2015) -
Incidental Dose to Pelvic Nodes in Bladder-Only Radiotherapy: Is It Clinically Relevant?
por: Lewis, Shirley, et al.
Publicado: (2017) -
Modified Houdek vault applicator for high-dose-rate brachytherapy: a technical report and case series
por: Krishnamurthy, Revathy, et al.
Publicado: (2021) -
Utilising alternative cystoscopic schedules to minimise cost and patient burden after trimodality therapy for muscle‐invasive bladder cancer
por: Krishnatry, Rahul, et al.
Publicado: (2023) -
Standard Chemoradiation and Conventional Brachytherapy for Locally Advanced Cervical Cancer: Is It Still Applicable in the Era of Magnetic Resonance–Based Brachytherapy?
por: Mittal, Prachi, et al.
Publicado: (2018)